65,437 trials
Refractory Chronic Cough
Primary: Cough Reflex Sensitivity to Capsaicin Measured by Maximal Cough Response (Emax) — 4.14; 4.14; 7.57; 3.66 Emax (Explosive coughs/15 sec) — p=< 0.0001
Behavior
Primary: Scores on the Certification Examination — 73.9; 73.1 scores on a scale
Refractory Benign Esophageal Strictures Caused by Caustic Ingestion
Primary: Clinical Success — 1 Participants
Heart Failure
Primary: Change From Baseline to Week 12 in Log-transformed N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) — -0.098; -0.047; 0.071; 0.057 log-transformed picograms per…
Urinary Incontinence, Stress · Fecal Incontinence
Primary: Urethral Opening Pressure (UOP) — 2.90411; -3.623431 cmH2O — p=0.07
Hypertension
Primary: Systolic Blood Pressure — 118; 127 mmHg
Sports Concussion
Primary: Liver Function Testing (Aspartate Transaminase [AST]/Alanine Transaminase [ALT] Ratios) to Screen for Adverse Events. — 1.57; 1.24 AST/ALT ratio
Glabellar Frown Lines
Primary: Number of Composite Responders at Month 1 — 64; 71; 72; 77 Participants
Cystic Fibrosis
Primary: Median Maximal Drug Concentration (Cmax) — 16.56; 12.5; 11.2; 3.0 mg/L
Chemotherapy-induced Nausea and Vomiting
Primary: Percentage of Participants With Nausea — 31; 47; 54; 53 percentage of participants
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) · Carnitine Palmitoyltransferase (CPT II) Deficiency · Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
Primary: Change From Baseline in Time Adjusted-Area Under the Curve (AUC/Time) for Workload During Cycle Ergometry at Week 24 — 423.594 watts — p=0.1518
Skin Laxity · Lipodystrophy
Primary: Number of Participants Who Had at Least One Grade Improvement on the Submental Skin Laxity Scale — 2 Participants
Relapsing Multiple Sclerosis
Primary: Adjusted Annualized Relapse Rate (ARR) at the End of Month 24 — 0.276; 0.218; 0.172 relapses/year — p=<0.0001
Healthy Non-smoker
Primary: CMax in Polyphenol Anthocyanin Concentrations — 8.7; 22.1; 7.6; 11.3 nmol/L
Relapsing Multiple Sclerosis
Primary: Total Number of Gadolinium-Enhancing (GdE) Lesions Assessed on Brain Magnetic Resonance Imaging (MRI) From Week 12 to Week 24 — 11.1; 1.9; 1.5 lesions — p=<0.0001